Prognostic Value of Bone Scintigraphy in Cardiac Amyloidosis
Authors:
- 1 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (1) , e34-e40
Abstract
Objectives: The prognostic value of bone scintigraphy in cardiac amyloidosis (CA) remains undetermined. We conducted a systematic review and meta-analysis on the association of cardiac uptake on bone scintigraphy with mortality in known or suspected CA. Patients and Methods: PubMed, Embase, and Cochrane library databases were searched up to November 2023 for studies that evaluated cardiac uptake on bone scintigraphy as a prognostic factor in the workup of CA. Hazards ratios (HRs) of high cardiac uptake for outcomes of all-cause or cardiac death were pooled and analyzed with stratifications according to the study populations, analytical methodologies, and radiotracers. Results: Fourteen studies (3325 patients) were finally included. In studies regarding known or suspected CA, visual grades were not prognostically significant, regardless of the threshold used, with pooled HRs of 2.25 (95% confidence interval [CI], 0.93–5.48), 1.55 (95% CI, 0.89–2.68), and 1.53 (95% CI, 0.95–2.47) for visual grades ≥1, ≥2, and ≥3, respectively. By contrast, high cardiac uptake on semiquantitative measurements (heart-to-contralateral lung ratio, n = 6; heart-to-whole-body ratio, n = 1) was associated with increased mortality (pooled HR = 2.27 [95% CI, 1.87–2.76] for all semiquantitative measurements; 2.26 [1.86–2.74] for heart-to-contralateral lung ratio only). No difference in prognostic significance was found across 3 different 99mTc-radiotracers (P = 0.619). However, high cardiac uptake was not predictive of mortality in aortic stenosis-related CA (pooled HR = 1.13 [95% CI, 0.96–1.32]). Conclusions: High semiquantitative cardiac uptake on bone scintigraphy is associated with an increased risk of mortality in patients with known or suspected CA.Keywords
This publication has 32 references indexed in Scilit:
- The Short and Long-Term Characteristics and Outcomes of Patients with Grade 1 Myocardial Uptake on Cardiac ScintigraphyESC Heart Failure, 2023
- Transthyretin Cardiac Amyloidosis in Patients After TAVR: Clinical and Echocardiographic Findings and Long Term SurvivalESC Heart Failure, 2021
- Association of Mortality With Aortic Stenosis Severity in OutpatientsJAMA Cardiology, 2021
- Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosisJournal of Nuclear Cardiology, 2021
- Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosisEuropean Journal of Heart Failure, 2020
- Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: Comparison of quantitative and semi-quantitative approachesJournal of Nuclear Cardiology, 2020
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imagingJournal of Nuclear Cardiology, 2019
- Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomesJournal of Nuclear Cardiology, 2017
- Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac ImagingJAMA Cardiology, 2016
- Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosisJournal of Nuclear Cardiology, 2015